Boston Scientific Corporation vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Boston Scientific Corporation trades at $42.71 (market cap $66.37B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $96.1. The key difference: State Street SPDR Bloomberg High Yield Bond ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | JNK | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Fixed Income |
52-Week High | $108.14 | $98.19 |
52-Week Low | $42.63 | $94.66 |
Enterprise Value | $75.94B | — |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
JNK trades at $95.76, down 0.18% on the day, with a bearish technical signal from moving averages and oscillators showing neutral momentum. The ETF maintains consistent dividend distributions, with recent payouts around $0.52-$0.53. Market sentiment is cautious amid Federal Reserve uncertainty and inflation concerns, while technical support sits near $95.
The outlook for JNK is clouded by potential Fed rate hikes and bond market volatility. High-yield bond ETFs face headwinds from rising yields, though demand for yield remains strong. Risks include interest rate sensitivity and economic slowdowns, while institutional flows indicate mixed confidence in fixed income assets.
Trailing returns across standard periods
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →